Thousands of women with ovarian cancer could benefit from a revolutionary drug combination after it was shown to significantly shrink tumours in almost half of patients with the disease.
The new treatment blocks tumour growth, helping keep the disease at bay for years. Experts said the “fantastic” and “very exciting” results from clinical trials of the drug combination, presented at the world’s largest cancer conference this weekend, showed it was “far more effective” than any available option for patients.
